Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease | Zendy

Michael D. Ezekowitz | Zendy; Rangadham Nagarakanti | Zendy; Herbert Noack | Zendy; Martina Brueckmann | Zendy; Claire Litherland | Zendy; Mark Jacobs | Zendy; Andreas Clemens | Zendy; Paul Reilly | Zendy; Stuart J. Connolly | Zendy; Salim Yusuf | Zendy; Lars Wallentin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease

Author(s) -

Michael D. Ezekowitz,

Rangadham Nagarakanti,

Herbert Noack,

Martina Brueckmann,

Claire Litherland,

Mark Jacobs,

Andreas Clemens,

Paul Reilly,

Stuart J. Connolly,

Salim Yusuf,

Lars Wallentin

Publication year - 2016

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.115.020950

Subject(s) - medicine , atrial fibrillation , cardiology , warfarin , valvular heart disease , dabigatran , stroke (engine) , mitral regurgitation , stenosis , hazard ratio , confidence interval , mechanical engineering , engineering

The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) compared dabigatran 150 and 110 mg twice daily with warfarin in 18 113 patients with atrial fibrillation. Those with prosthetic heart valves, significant mitral stenosis, and valvular heart disease (VHD) requiring intervention were excluded. Others with VHD were included.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research